US/UK/Canada

Share

Pick a time period -
Tags ( Active)

XVIVO Perfusion AB (publ) Interim Report January – September 2018

GOOD SALES GROWTH DRIVEN BY WARM PERFUSIONTHIRD QUARTER 2018 (JUL - SEP) • Total net sales in the quarter amounted to SEK 40.9 (32.3) million, corresponding to an increase of 27 percent. The increase corresponds to 18 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 40.3 (31.6) million, corresponding to an increase of 27 percent in SEK. Sales of non-durable goods increased by 18 percent in local currency.• Sales from warm perfusion* showed a growth record of more than 60 percent during the quarter. Sales from warm perfusion represented 40 percent

XVIVO Perfusion Interim report January – June 2016

ACQUISITION OF VIVOLINE STRENGTHENS XVIVO’S PRODUCT AND R&D PORTFOLIOSECOND QUARTER 2016 (APR – JUN) • Net sales in the quarter amounted to SEK 34.5 (29.1) million, corresponding to an increase of 18 percent. Net sales of non-Durable goods* in the quarter amounted to SEK 29.8 (27.4) million, corresponding to an increase of 9 percent in SEK and 11 percent in local currency.• Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 51 percent and amounted to SEK 6.9 (4.6) million, corresponding to an EBITDA margin of 20 percent. One-time

Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution™

STEEN Solution™ was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering from metastatic lung sarcoma through In-Vivo Lung Perfusion (IVLP).  This was also the first time STEEN Solution was used to perfuse a lung on In-Vivo i.e. on a living patient. The aim of the study is to prove safety and evaluate the ability to use STEEN Solution™ to improve isolated tissue therapy.A leading hospital enrolled their first patient into a clinical trial to provide chemotherapy to patients suffering from lung sarcomas.  According to the 2016 data from the

There are no items matching the current filter
There are no more items matching the current filter
Back to top